GC

2018–Present

Challenge towards a healthy future for people
from a history of challenge and passion

• 2023

  • GC Biopharma Received WHO Pre-Qualification for Filling and Finish Plant in Ochang
  • GC Biopharma Exceeded 300 million doses of flu vaccine production
  • GC Biopharma Received WHO Pre-Qualification for BARYCELA
  • GC Biopharma Established Corporate Compliance Management System

• 2022

  • GC Published 1st Sustainability Report
  • GC Genome was designated as a Good Clinical Laboratory Practice (GCLP)
  • GC (holding company) and GC Cell acquired US-based BioCentriq

• 2021

  • GC Wellbeing completed the Eumseong Innovative Factory in Chungcheongbuk-do
  • UBcare acquired an "EMR System Certification" for its "Ysarang" from the Ministry of Health and Welfare
  • GC acquired Genes Laboratories
  • Launched GC Cell by integrating GC LabCell and GC Cell
  • GC LabCell-Artiva and MSD exported 2 trillion won worth of CAR-NK technology
  • GC Biopharma obtained marketing approval of "Hunterase ICV" in Japan for severe Hunter syndrome, first in the world, and also obtained marketing approval of "GreenGene F" in China

• 2020

  • Established Green Vet
  • GC Labs was designated as a clinical performance test institution for in vitro diagnostic medical devices, first in Korea
  • GC acquired Able Analytics, a consulting firm specializing in big data analysis
  • GC Biopharma obtained marketing approval of the next generation of varicella vaccine (Barycela inj.)
  • GC Biopharma obtained marketing approval of "Hunterase" in China for Hunter syndrome
  • GC Care acquired UBcare

• 2019

  • GCBiopharma exceeded 200 million doses of flu vaccine production
  • IPO of GC Wellbeing
  • Established GCCL

• 2018

  • Green Cross Holdings makes a new start as "GC"
  • GC Biopharma receives $200 Million Export Tower Award
  • GC Cell has completed a Cell Center

2010 - 2017

Challenge towards a global leader in the health industry
with a driving force of pioneering and accumulated expertise

• 2017

  • Established CUREVO
  • GC Genome obtained an accreditation from the College of American Pathologists (CAP)

• 2016

  • GC Biopharma obtained a WHO PQ for GC Flu Quadrivalent
  • GC Biopharma obtained a marketing approval of a Tetanus-Diphtheria (GC TD vaccine) vaccine, Korea’s the first TD vaccine
  • IPO of GC LabCell

• 2015

  • GC MS acquired Ceragem Medisys Inc. (current GCMedis). Started diabetes business
  • GC Labs received a commendation from the Minister of Science, ICT and Future Planning at the "2015 Korea ICT Innovation Awards"
  • GC Biopharma obtained a marketing approval of ”GC Flu Quadrivalent", the world’s fourth quadrivalent flu vaccine
  • GC Biopharma obtained a marketing approval of "GC Flu H5N1", Korea’s the first avian influenza vaccine

• 2014

  • IPO of GCMS
  • GC MS obtained a marketing approval of a "multi-diagnostic influenza test kit", first in the world
  • GC Biopharma produced over 100 million doses of flu vaccines, the first in Korea
  • GC Biopharma was awarded with the $100 Million Export Tower Award

• 2013

  • Established GC Genome
  • GC MS merged with the Gambro Korea Solution, and started the hemodialysis solution business
  • GC Biopharma started construction of the blood plasma-derived products facility
  • for Thai Red Cross in Thailand GC Biopharma completed the GC R&D Center
  • , the largest research institute in the Korean pharmaceutical industry

• 2012

  • GC Biopharma obtained a marketing approval of "Hunterase", the world’s
  • 2nd Hunter Syndrome treatment GC Biopharma acquired INNOCELL
  • corporation and launched GC Cell

• 2011

  • Established GC LabCell
  • GC Biopharma obtained a marketing approval of "SHINBARO",
  • a natural medicine for osteoarthritis treatment

2000 - 2009

History made by
each step of effort

• 2009

  • Established Future Foundation of Korea
  • GC Biopharma established Hwasun Plant, Korea's first vaccine production facility
  • GC Biopharma obtained a marketing approval of "Green Flu", the H1N1 vaccine, and "GC Flu", Korea’s
  • the first flu vaccine GC Biopharma completed the Ochang Plant, a state-of-the-art blood product and gene recombination production facility

• 2008

  • GC Biopharma obtained a marketing approval of "Green Gene", the world’s fourth recombinant treatment for hemophilia A

• 2007

  • Established GC Invacfarm

• 2006

  • GC MS obtained a marketing approval of a magnetic diagnostic reagent for the first time in Korea

• 2005

  • Established Mogam Science Scholarship Foundation
  • GC Wellbeing obtained a marketing approval of a placenta injection (Laennec)

• 2004

  • Established GC Wellbeing

• 2003

  • Established GCMS
  • Established GC Care

• 2001

  • Established GCEM
  • GC Biopharma acquired Sang-A Pharmaceuticals

• 2000

  • Established a urokinase production plant in North Korea

1967 - 1999

A pioneering road
that others have not taken

• 1995

  • Established GC China. Established a vaccine plant in Indonesia

• 1993

  • Obtained marketing approval of a chickenpox vaccine (Suduvax), second in the world

• 1990

  • Established Korea Hemophilia Foundation (KHF)
  • MOGAM Institute for Biomedical Research obtained marketing approval of an AIDS Diagnosis Reagent

• 1989

  • IPO of GC Biopharma

• 1988

  • Obtained marketing approval of the world's first vaccine against hemorrhagic fever with renal syndrome (Hantavax)

• 1984

  • Established MOGAM Institute for Biomedical Research

• 1983

  • Obtained marketing approval of a hepatitis-B vaccine (Hepavax-B) for the third time in the world

• 1982

  • Established GC Labs, and obtained marketing approval of an intravenous injection (I.V.-Globulin)

• 1978

  • IPO of GC

• 1974

  • Obtained marketing approval of the antihemophilic factor (AHF) product

• 1973

  • First in Korea to obtain approval of a stroke treatment (urokinase)

• 1971

  • Renamed to GC Corp. obtained marketing approval of blood products, first in Korea

• 1968

  • Constructed the Singal Plant

• 1967

  • Established Sudo Microorganism Medical Supplies Co.